Mar 1, 2026 | CagriSema Week of Reckoning: Analysts Revise, Novo Regroups | YUVIWEL Approved + PRV Voucher | Weekend Edition

Seven analyst downgrades, Deutsche Bank at Hold with a 275 DKK target, Morningstar cutting CagriSema peaksales from $13B to $8B. We cover the open-label design limitation constraining Novo's patient-reported outcome claims and where the differentiation argumenthas to go next. Plus GSK's $950M activin bet, China licensing at record pace, Lilly's ACHIEVE-3 win. FDA approved YUVIWEL with a $100–150M PRV. Dupixent'sninth indication. Pfizer/Astellas bladder cancer data that deserved more coverage. Week ahead: Imcivree Mar 20, Kresladi Mar 28, pelacarsen H1 readout.